Quantum BioPharma Ltd. (QNTM)
NASDAQ: QNTM · Real-Time Price · USD
6.86
-0.16 (-2.28%)
At close: May 29, 2026, 4:00 PM EDT
6.82
-0.04 (-0.58%)
After-hours: May 29, 2026, 7:54 PM EDT
Quantum BioPharma Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
17
Market Cap
44.10M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Gossamer Bio | 55.54M |
| Plus Therapeutics | 5.21M |
| Nutriband | 2.04M |
| RenovoRx | 1.49M |
| Hyperion DeFi | 1.04M |
| aTyr Pharma | 190.00K |
QNTM News
- 12 days ago - Quantum BioPharma Reaches Key Midpoint Milestone in Groundbreaking Imaging Study with Massachusetts General Hospital - GlobeNewsWire
- 22 days ago - Quantum Reports Strengthened Liquidity, Reduced Cash Burn, and Disciplined Cost Management in First Quarter 2026 - GlobeNewsWire
- 4 weeks ago - Quantum BioPharma Provides Corporate Update - GlobeNewsWire
- 5 weeks ago - Quantum BioPharma Licensee Unbuzzd Wellness Inc. Appoints Richard Buzbuzian as CEO to Lead Nationwide Commercialization of Innovative, Clinically Validated Hangover Remedy and Alcohol Metabolism Accelerant - GlobeNewsWire
- 2 months ago - Quantum BioPharma submits Lucid-21-302 new drug application to the FDA - TheFly
- 2 months ago - Quantum BioPharma Submits Investigational New Drug (IND) Application to United States Food and Drug Administration (FDA) for Lucid-MS Phase Two Clinical Trial in Multiple Sclerosis - GlobeNewsWire
- 2 months ago - Quantum BioPharma signs letter of intent with Allucent to conduct Lucid-MS trial - TheFly
- 2 months ago - Quantum BioPharma signs letter of intent with Allucent to conduct Lucid-MS trial - TheFly